The table below is a review of notable updates that occurred in April 2025 for investigational products in development.

AstraZeneca is to sell European rights to its cholesterol drug Crestor (rosuvastatin) to Germany’s Grunenthal. Crestor is a statin and at its peak generated annual revenues of more than $7 ...

For almost 60 years, measuring cholesterol levels in the blood has been the best way to identify individuals at high risk of ...

(NewsNation) — AstraZeneca’s experimental pill has shown promise in reducing “bad” cholesterol, raising expectations for more convenient alternatives in treatment options. AstraZenca is ...

AstraZeneca Plc’s Chief Executive Officer Pascal Soriot warned that trade tariffs are not the best way to manage pharmaceuticals and that drugmakers are calling for no additional US levies on ...

Australian study finds no adverse impact of repeated Covid vaccinations on metabolism, inflammation, or cardiovascular ...

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...

Inflammation is likely a key player in atherosclerosis and related cardiovascular events, but questions remain about its role ...

They have a cholesterol level above 70 ... is it fair to say that under all contemplated scenarios and in light of AstraZeneca's actions over the next two to three years, tariffs are not material ...

COPD cases are rising in women. Uncover the latest insights to enhance diagnosis and treatment in your women patients.